Tuesday, March 27, 2007
Isis cholesterol drug lowers LDL levels
Isis cholesterol drug lowers LDL levels
26th March 2007, By Victoria Harrison
Isis Pharmaceuticals has said new results from its monotherapy phase II clinical trial of cholesterol drug showed improvements in LDL cholesterol.
Patients with high cholesterol were treated for ten weeks with 400 mg/week of the drug ISIS 301012. In this study, increasing the dose of ISIS 301012 to 400 mg/week was well tolerated and further reduced atherogenic lipids, with median improvements in LDL-cholesterol of 70%.
Read the full report here @ Pharmaceutical Business Review Online
26th March 2007, By Victoria Harrison
Isis Pharmaceuticals has said new results from its monotherapy phase II clinical trial of cholesterol drug showed improvements in LDL cholesterol.
Patients with high cholesterol were treated for ten weeks with 400 mg/week of the drug ISIS 301012. In this study, increasing the dose of ISIS 301012 to 400 mg/week was well tolerated and further reduced atherogenic lipids, with median improvements in LDL-cholesterol of 70%.
Read the full report here @ Pharmaceutical Business Review Online
Labels: atherosclerosis, heart-disease
Hemochromatosis gene linked to stroke risk
Hemochromatosis gene linked to stroke risk
Mar 26, 2007
NEW YORK (Reuters Health) - Patients with a specific gene variation for hereditary hemochromatosis, an autosomal recessive disease associated with increased iron accumulation, have more than double the risk of stroke, new research suggests.
Hemochromatosis affects how the body metabolizes iron, which results an iron build-up in the liver. Without treatment, the condition causes liver enlargement that can lead to cirrhosis or liver cancer. The disease can also cause diabetes, heart disease, arthritis, and other serious conditions.
Read the full report here @ Reuters, UK
Mar 26, 2007
NEW YORK (Reuters Health) - Patients with a specific gene variation for hereditary hemochromatosis, an autosomal recessive disease associated with increased iron accumulation, have more than double the risk of stroke, new research suggests.
Hemochromatosis affects how the body metabolizes iron, which results an iron build-up in the liver. Without treatment, the condition causes liver enlargement that can lead to cirrhosis or liver cancer. The disease can also cause diabetes, heart disease, arthritis, and other serious conditions.
Read the full report here @ Reuters, UK
Labels: heart-disease
Pfizer says new studies show higher dose of Lipitor slows atherosclerosis
Pfizer says new studies show higher dose of Lipitor slows atherosclerosis
26 Mar 2007
LONDON (AFX) - Pfizer Inc said results from two new imaging trials show a higher dose of its cholesterol-fighting drug Lipitor stopped the progression of atherosclerosis in patients with coronary heart disease or familial hypercholesterolemia (FH).
The results are part of three, two-year clinical trials, involving over 2,800 patients, designed to investigate the efficacy of torcetrapib in combination with Lipitor compared to Lipitor alone.
Read the full report from here @ Forbes
26 Mar 2007
LONDON (AFX) - Pfizer Inc said results from two new imaging trials show a higher dose of its cholesterol-fighting drug Lipitor stopped the progression of atherosclerosis in patients with coronary heart disease or familial hypercholesterolemia (FH).
The results are part of three, two-year clinical trials, involving over 2,800 patients, designed to investigate the efficacy of torcetrapib in combination with Lipitor compared to Lipitor alone.
Read the full report from here @ Forbes
Labels: atherosclerosis, heart-disease
PermaLink - Pfizer says new studies show higher dose of Lipitor slows atherosclerosis posted by Ecacofonix : 4:09 AM
0 Comments
Crestor Effective at Halting Early Atherosclerosis
Crestor Effective at Halting Early Atherosclerosis
This press release issued by Eurekalert says that an international study using ultrasound technology has found that the most potent cholesterol-lowering drug is also effective at halting early changes in the blood vessels that can lead to atherosclerosis.
Results from the study were reported at the annual meeting of the American College of Cardiology in New Orleans and were published on-line by the Journal of the American Medical Association. The research involved people with moderately elevated cholesterol levels who didn't qualify for treatment under national guidelines.
Read the full news report from the Hindu
This press release issued by Eurekalert says that an international study using ultrasound technology has found that the most potent cholesterol-lowering drug is also effective at halting early changes in the blood vessels that can lead to atherosclerosis.
Results from the study were reported at the annual meeting of the American College of Cardiology in New Orleans and were published on-line by the Journal of the American Medical Association. The research involved people with moderately elevated cholesterol levels who didn't qualify for treatment under national guidelines.
Read the full news report from the Hindu
Labels: atherosclerosis, heart-disease
PermaLink - Crestor Effective at Halting Early Atherosclerosis posted by Ecacofonix : 4:02 AM
0 Comments
Subscribe to Posts [Atom]